Nodular regenerative hyperplasia in patients with inflammatory bowel disease treated with azathioprine

Vernier-Massouille, G.; Cosnes, J.; Lemann, M.; Marteau, P.; Reinisch, W.; Laharie, D.; Cadiot, G.; Bouhnik, Y.; de Vos, M.; Boureille, A.; Duclos, B.; Seksik, P.; Mary, J.-Y.; Colombel, I.-F.
October 2007
Gut;Oct2007, Vol. 56 Issue 10, p1404
Academic Journal
Aim: To assess the characteristics and clinical course of nodular regenerative hyperplasia (NRH) in patients with inflammatory bowel disease treated with azathioprine, so as to estimate the frequency of this complication and search for risk factors. Methods: Cases were identified through a systematic survey of patients followed at 11 centres. At one centre, the cumulative risk of NRH was estimated and a case-control study was undertaken to identify risk factors. Results: 37 cases of NRH (30 male, 7 female) were identified between 1994 and 2005. The median dose of azathioprine was 2 mg/kg/d (range 1 .5 to 3.0). The median time between the start of azathioprine and the diagnosis of NRH was 48 months (range 6 to 187). After a median follow up period of 16 months (range 1 to 138), 14 patients developed complications of portal hypertension. Using multivariate analysis, male sex and stricturing behaviour were the two risk factors associated with NRH in patients treated with azathioprine. The cumulative risk calculated from the database (one centre) was 0.5% at 5 years (95% confidence interval, 0.11 to 0.89) and 1.25% at 10 years (0.29 to 2.21). Conclusions: NRH is a rare but potentially severe complication of azathioprine in patients with inflammatory bowel disease. Clinicians should be aware of this complication, and should monitor liver function tests and platelet counts closely in their patients.


Related Articles

  • Role of alkaline phosphatase in colitis in man and rats. A Tuin // Gut;Mar2009, Vol. 58 Issue 3, p379 

    BACKGROUND AND AIMS: Crohn’s disease (CD) and ulcerative colitis (UC) are chronic multifactorial inflammatory bowel diseases (IBDs) with unknown aetiology, but a deregulated mucosal immune response to gut-derived bacterial antigens is thought to be involved. Toll-like receptor ligands,...

  • Molecular prediction of disease risk and severity in a large Dutch Crohn’s disease cohort. R K Weersma // Gut;Mar2009, Vol. 58 Issue 3, p388 

    BACKGROUND: Crohn’s disease and ulcerative colitis have a complex genetic background. We assessed the risk for both the development and severity of the disease by combining information from genetic variants associated with inflammatory bowel disease (IBD). METHODS: We studied 2804...

  • Inflammatory Bowel Disorders.  // Current Medical Literature: Gastroenterology;2011, Vol. 30 Issue 1, p21 

    The article discusses various research that explored the different aspects of inflammatory bowel disorders. One of the studies dealt with the changes in surgical resection rates and medical treatments for Crohn's disease. Another research focused on the association of pre-operative management...

  • New therapeutic approach in inflammatory bowel disease. PAPA, A.; MOCCI, G.; SCALDAFERRI, F.; BONIZZI, M.; FELICE, C.; ANDRISANI, G.; GASBARRINI, A. // European Review for Medical & Pharmacological Sciences;Jan2009 Supplement, Vol. 13 Issue S-1, p33 

    In the last decade, biologic agents, in particular infliximab and adalimumab, have deeply changed the therapeutic armamentarium of inflammatory bowel disease (IBD). However, these drugs have a number of contraindications and side-effects that physicians should know so to avoid and eventually...

  • Relationship between the polymorphism of tumor necrosis factor-α-308 G>A and susceptibility to inflammatory bowel diseases and colorectal cancer: a meta-analysis. Wang Fan; Wang Maoqing; Chen Wangyang; Hu Fulan; Li Dandan; Ren Jiaojiao; Dong Xinshu; Cui Binbin; Zhao Yashuang // European Journal of Human Genetics;Apr2011, Vol. 19 Issue 4, p432 

    Inflammatory bowel disease (IBD) and colorectal cancer (CRC) are common health problems worldwide. Tumor necrosis factor (TNF) is a type of cytokine that induces inflammation and inhibits tumorigenesis. Several studies have assessed the relationship between the polymorphism of TNF-α-308 G>A...

  • Does It Matter Where You Are Hospitalized for Inflammatory Bowel Disease? A Nationwide Analysis of Hospital Volume. Ananthakrishnan, Ashwin N.; McGinley, Emily L.; Binion, David G. // American Journal of Gastroenterology;Nov2008, Vol. 103 Issue 11, p2789 

    OBJECTIVE: To examine if a high hospital volume was associated with superior outcomes in inflammatory bowel disease (IBD) patients requiring hospitalization. METHODS: This was a cross-sectional study using data from the Nationwide Inpatient Sample (NIS 2004). IBD-related hospitalizations were...

  • Role of Procalcitonin in Infectious Gastroenteritis and Inflammatory Bowel Disease. Kelvin Thia; Edwin Chan; Khoon-Lin Ling; Wai-Yoong Ng; Edward Jacob; Choon-Jin Ooi // Digestive Diseases & Sciences;Nov2008, Vol. 53 Issue 11, p2960 

    Abstract   Background and Aim We have evaluated procalcitonin (PCT) as a diagnostic marker for bacterial gastroenteritis (GE) and as a disease activity marker in inflammatory bowel disease (IBD) patients. Methods This was a prospective single-center study performed over a 1-year...

  • Patients with Inflammatory Bowel Disease Are at Risk for Vaccine-Preventable Illnesses. Melmed, Gil Y.; Ippoliti, Andrew F.; Papadakis, Konstantinos A.; Tran, Tram T.; Birt, Jaime L.; Lee, Susie K.; Frenck, Robert W.; Targan, Stephan R.; Vasiliauskas, Eric A. // American Journal of Gastroenterology;Aug2006, Vol. 101 Issue 8, p1834 

    BACKGROUND: Patients with chronic, immune-mediated conditions such as inflammatory bowel disease (IBD) are often treated with long-term immunosuppressive therapies, potentially increasing their risk of developing an infection. Empiric data suggest that vaccines are underutilized in...

  • Five Cases of De Novo Inflammatory Bowel Disease After Orthotopic Liver Transplantation. Wörns, Marcus A.; Lohse, Ansgar W.; Neurath, Markus F.; Croxford, Andrew; Otto, Gerd; Kreft, Andreas; Galle, Peter R.; Kanzler, Stephan // American Journal of Gastroenterology;Aug2006, Vol. 101 Issue 8, p1931 

    Immunosuppression is currently the treatment of choice for severe inflammatory bowel disease (IBD). Thus, it was anticipated that the course of preexisting IBD should improve after orthotopic liver transplantation (OLT). Despite sufficient allograft immunosuppressive therapy, however,...


Read the Article


Sign out of this library

Other Topics